{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Herbst RS"],"funding":["NCI NIH HHS"],"pagination":["1514-24"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4654466"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(7)"],"pubmed_abstract":["The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are no approved targeted therapies specific to advanced lung SCC, although The Cancer Genome Atlas project and similar studies have detected a significant number of somatic gene mutations/amplifications in lung SCC, some of which are targetable by investigational agents. However, the frequency of these changes is low (5%-20%), making recruitment and study conduct challenging in the traditional clinical trial setting. Here, we describe our approach to development of a biomarker-driven phase II/II multisubstudy \"Master Protocol,\" using a common platform (next-generation DNA sequencing) to identif"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400."],"pmcid":["PMC4654466"],"funding_grant_id":["R01 CA155196","P30 CA046934","U10 CA105409","U10 CA180819","U10CA180819","U10 CA180834","U10 CA180846","R01CA155196","U10 CA180888","U10 CA180833","UG1 CA233340","U10CA180888"],"pubmed_authors":["Sparks D","Schwartz LH","Hirsch FR","Abrams JS","Wholley D","Miwa C","Sigal EV","Vokes E","Herbst RS","Yelensky R","Papadimitrakopoulou VA","Blanke CD","Redman MW","Mack PC","Sigman CC","Miller VA","Blumenthal GM","Malik S","Allen JD","Zhou Y","Li Y","Ramalingam SS","Kelloff GJ","Bradley JD","Gandara DR","LeBlanc M"],"additional_accession":[]},"is_claimable":false,"name":"Lung Master Protocol (Lung-MAP)-A Biomarker-Driven Protocol for Accelerating Development of Therapies for Squamous Cell Lung Cancer: SWOG S1400.","description":"The Lung Master Protocol (Lung-MAP, S1400) is a groundbreaking clinical trial designed to advance the efficient development of targeted therapies for squamous cell carcinoma (SCC) of the lung. There are no approved targeted therapies specific to advanced lung SCC, although The Cancer Genome Atlas project and similar studies have detected a significant number of somatic gene mutations/amplifications in lung SCC, some of which are targetable by investigational agents. However, the frequency of these changes is low (5%-20%), making recruitment and study conduct challenging in the traditional clinical trial setting. Here, we describe our approach to development of a biomarker-driven phase II/II multisubstudy \"Master Protocol,\" using a common platform (next-generation DNA sequencing) to identif","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015 Apr","modification":"2025-06-01T03:25:17.379Z","creation":"2020-11-07T09:50:27Z"},"accession":"S-EPMC4654466","cross_references":{"pubmed":["25680375"],"doi":["10.1158/1078-0432.ccr-13-3473","10.1158/1078-0432.CCR-13-3473"]}}